Akademik Veri Yönetim Sistemi
II. International Cancer Days Congress, Sivas, Türkiye, 16 - 18 Eylül 2021, cilt.1, ss.148-156
Gastric cancer is the fourth most common cancer worldwide and the third most common cause of cancer-related death. Gastric cancer begins when cells with the ability to divide uncontrollably form in the lining of your stomach. These cells can then develop into a tumor. In stomach cancer, the cells or tumors that cause the disease grow slowly and the symptoms of the disease are observed in the patient after a certain period of time. This causes delays in the diagnosis and treatment of the disease. For this reason, these delays can be avoided by having the necessary tests and controls performed at certain time intervals. Helicobacter pylori, a common bacterium that causes ulcers, inflammation of the intestines called gastritis, long-term pernicious anemia and anomalies in the stomach called polyps can cause gastric cancer. In addition, obesity, the use of alcohol and cigarettes, and not paying attention to diet can also trigger the formation of the disease. A multidisciplinary approach is mandatory in the planning of gastric cancer treatment. The multidisciplinary team should consist of at least one surgeon, pathologist, gastroenterologist, medical and radiation oncologists. New drug molecules are studied in order to create a more effective treatment profile, and reduce the undesirable side effects of drugs commonly used in the treatment of gastric cancer. The scope of these studies consists of creating suitable formulations using biocompatible and non-toxic polymers or carrier systems for targeted therapy, and conducting preclinical and clinical studies.